Business Context and Reporting Period
This Form 8-K was filed by Gemini Therapeutics, Inc. (not Disc Medicine, Inc.) on August 12, 2021. The filing reports the Company's financial results for the quarter ended June 30, 2021. The registrant is incorporated in Delaware and trades on The Nasdaq Global Market under the symbol GMTX.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced via a press release attached as Exhibit 99.1, but the text of the press release is not included in the input data.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the provided text. The filing references the attached press release for the full announcement of results.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, management commentary, risk factors, or details on contingencies. It notes that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Gemini Therapeutics, Inc. (GMTX), as the input metadata incorrectly listed "Disc Medicine, Inc."
- Locate and review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended June 30, 2021.
- Confirm the legal status of the financial data as "furnished" rather than "filed" for liability purposes.